Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Boehringer Ingelheim will pay about $245 million to acquire the Austrian oncolytic viral therapy start-up ViraTherapeutics. The firm is developing a vesicular stomatitis virus that infects and replicates in cancer cells, causing the cells to burst and die. That causes inflammation in the tumor, which can help cancer immunotherapies, such as checkpoint inhibitors, work when they wouldn’t have otherwise. Earlier this year, Merck & Co. paid about $400 million for the oncolytic virus firm Viralytics, and Janssen Biotech acquired BeneVir for $140 million.
This article has been sent to the following recipient: